Recombinant glycoprotein based vaccine for Chandipura virus infection.
Chandipura virus (CHPV) has emerged as an important pediatric encephalitis-causing pathogen with very high mortality in India. No specific vaccine or treatment is available till date. We attempted to prepare a candidate vaccine employing recombinant CHPV Glycoprotein (rGp). The Glycoprotein gene (G-gene) of CHPV was expressed using Baculovirus expression system. The rGp was purified by HPLC and used for mice immunization, 3 doses, and 4 weeks apart. One microgram rGp was found to be optimum. Sero-conversion was observed as early as 2nd week by detecting anti-CHPV IgG antibodies. Antibody titres were immunogen-concentration dependent. Intracerebral challenge of the immunized mice with 100 LD(50) of the homologous strain demonstrated 90% protection. In in vitro neutralization, antibodies from the immunized mice were able to neutralize heterologous viruses. There was 60% T cell proliferation observed against rGp in immunized mice. The study shows that rGp induces both arms of immune response and represents an ideal vaccine candidate for further evaluations.
Venkateswarlu
C H
CH
Hepatitis Division, National Institute of Virology, Microbiological Containment Complex, Sus Road, Pashan, Pune 411021, India.
Arankalle
V A
VA
D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification / Q000378:metabolism; D051379:Mice; D018353:Rhabdoviridae Infections / Q000276:immunology* / Q000517:prevention & control; D014709:Vero Cells; D018116:Vesiculovirus / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification / Q000378:metabolism; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D006023:Glycoproteins; D014764:Viral Proteins; D014765:Viral Vaccines